Piper Sandler Increases Kenvue (NYSE:KVUE) Price Target to $21.00

Kenvue (NYSE:KVUE) had its price target boosted by Piper Sandler from $20.00 to $21.00 in a report released on Monday, Benzinga reports. Piper Sandler currently has a neutral rating on the stock.

KVUE has been the subject of a number of other research reports. JPMorgan Chase & Co. upped their price objective on Kenvue from $22.00 to $24.00 and gave the company an overweight rating in a research report on Wednesday, August 7th. Deutsche Bank Aktiengesellschaft upped their price target on shares of Kenvue from $23.00 to $24.00 and gave the company a buy rating in a research report on Wednesday, August 7th. UBS Group boosted their target price on shares of Kenvue from $20.00 to $22.00 and gave the company a neutral rating in a research report on Wednesday, August 7th. Citigroup reduced their target price on shares of Kenvue from $21.00 to $20.00 and set a neutral rating for the company in a report on Wednesday, July 10th. Finally, Royal Bank of Canada reissued an outperform rating and set a $24.00 price objective on shares of Kenvue in a research report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of Hold and an average target price of $22.10.

Kenvue Price Performance

KVUE opened at $23.03 on Monday. The company’s 50-day simple moving average is $21.21 and its two-hundred day simple moving average is $20.03. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.68 and a current ratio of 0.99. The stock has a market capitalization of $44.10 billion, a P/E ratio of 29.52, a P/E/G ratio of 2.92 and a beta of 1.40. Kenvue has a 52-week low of $17.67 and a 52-week high of $23.55.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.28 by $0.04. Kenvue had a net margin of 7.23% and a return on equity of 21.80%. The company had revenue of $4 billion for the quarter, compared to the consensus estimate of $3.93 billion. During the same quarter in the prior year, the firm earned $0.32 earnings per share. The firm’s revenue for the quarter was down .3% compared to the same quarter last year. As a group, analysts predict that Kenvue will post 1.08 EPS for the current year.

Kenvue Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, August 28th. Shareholders of record on Wednesday, August 14th were issued a dividend of $0.205 per share. The ex-dividend date was Wednesday, August 14th. This is a boost from Kenvue’s previous quarterly dividend of $0.20. This represents a $0.82 dividend on an annualized basis and a yield of 3.56%. Kenvue’s dividend payout ratio (DPR) is currently 105.13%.

Institutional Trading of Kenvue

Institutional investors have recently made changes to their positions in the business. D.A. Davidson & CO. boosted its stake in Kenvue by 61.7% in the 4th quarter. D.A. Davidson & CO. now owns 57,386 shares of the company’s stock worth $1,236,000 after purchasing an additional 21,889 shares during the period. Corient Private Wealth LLC lifted its holdings in shares of Kenvue by 202.8% in the fourth quarter. Corient Private Wealth LLC now owns 365,667 shares of the company’s stock worth $7,873,000 after buying an additional 244,925 shares in the last quarter. Assetmark Inc. boosted its position in shares of Kenvue by 2,337.2% during the fourth quarter. Assetmark Inc. now owns 39,995 shares of the company’s stock worth $861,000 after acquiring an additional 38,354 shares during the last quarter. EverSource Wealth Advisors LLC grew its stake in Kenvue by 69.5% during the fourth quarter. EverSource Wealth Advisors LLC now owns 2,326 shares of the company’s stock valued at $50,000 after acquiring an additional 954 shares in the last quarter. Finally, US Bancorp DE increased its holdings in Kenvue by 111.7% in the 4th quarter. US Bancorp DE now owns 103,733 shares of the company’s stock valued at $2,233,000 after acquiring an additional 54,729 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.